Abstract
AbstractThe Medical Services Advisory Committee (MSAC) is an independent non-statutory committee established by the Australian government to provide recommendations on public reimbursement of technologies and services, other than pharmaceuticals. MSAC has established approaches for undertaking health technology assessment (HTA) of investigative services and codependent technologies. In 2016, MSAC published its clinical utility card (CUC) Proforma, an additional tool to guide assessments of genetic testing for heritable conditions. We undertook a review and narrative synthesis of information extracted from all MSAC assessments of genetic testing for heritable conditions completed since 2016, regardless of the HTA approach taken. Ten assessments met our inclusion criteria, covering a range of testing methods (from gene panels to whole-exome sequencing) and purposes (including molecular diagnosis, genetic risk assessment, identification of congenital anomaly syndromes, and carrier screening). This analysis identified a range of methodological and policy challenges such as how to incorporate patient and societal preferences for the health and non-health outcomes of genomic testing, how best to capture the concept of co-production of utility, and how to engage clinicians as referrers for genomics tests whilst at the same time ensuring equity of access to a geographically dispersed population. A further challenge related to how qualitative assessments of patient and community needs influenced the evidence thresholds against which decisions were made. These concepts should be considered for incorporation within the value assessment frameworks used by HTA agencies around the world.
Funder
National Health and Medical Research Council
Publisher
Springer Science and Business Media LLC
Subject
Genetics(clinical),Public Health, Environmental and Occupational Health,Epidemiology
Reference39 articles.
1. Australian Government Department of Health (2020) Health technology assessment. https://www1.health.gov.au/internet/hta/publishing.nsf/Content/home-1 Accessed 19 May 2021
2. Banta D, Jonsson E (2009) History of HTA: introduction. Int J Technol Assess Health Care 25(S1):1–6
3. Bombard Y, Bach PB, Offit K (2013) Translating genomics in cancer care. J Natl Compr Canc Netw 11(11):1343–1353
4. Burke W, Atkins D, Gwinn M, Guttmacher A, Haddow J, Lau J, Palomaki G, Press N, Richards CS, Wideroff L (2002) Genetic test evaluation: information needs of clinicians, policy makers, and the public. Am J Epidemiol 156(4):311–318
5. Cornel MC, Rigter T, Jansen ME, Henneman L (2021) Neonatal and carrier screening for rare diseases: how innovation challenges screening criteria worldwide. J Community Genet 12(2):257–265. https://doi.org/10.1007/s12687-020-00488-y
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献